In Re: Aggrenox Antitrust Litigation

Track this case

Case overview

Case Number:

3:14-md-02516

Court:

Connecticut

Nature of Suit:

Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Stefan R. Underhill

Firms

Companies

Sectors & Industries:

December 09, 2015
Drug Cos. Ask Court To Delay Decision Over Aggrenox Market

Boehringer Ingelheim and Teva urged a Connecticut federal court Tuesday to hold off on devising a method for determining the relevant product market in multidistrict litigation accusing the drugmakers of scheming to keep generic versions of the stroke-prevention drug Aggrenox off the market, saying it was premature to do so.
November 16, 2015
Boehringer, Teva Slam Aggrenox Buyers' Doc Production

Boehringer Ingelheim and Teva on Friday told a Connecticut federal judge that the direct purchasers accusing them in multidistrict litigation of scheming to keep generic versions of the stroke-prevention drug Aggrenox off the market won't cooperate in discovery, by refusing to search for more than three terms.
November 02, 2015
BCBS Fights Dismissal Bid In Aggrenox Pay-For-Delay Suit

Louisiana Blue Cross/Blue Shield urged a Connecticut federal court Friday not to dismiss the insurer's state antitrust claims from multidistrict litigation accusing Boehringer Ingelheim Pharmaceuticals Inc. of scheming to keep generic versions of the stroke-prevention drug Aggrenox off the market, saying they are supported by several states' laws.
September 22, 2015
Aggrenox Buyers Blast Discovery Bid In Antitrust MDL

Direct purchasers in multidistrict litigation accusing Boehringer Ingelheim Pharmaceuticals Inc. of scheming to keep generic versions of the stroke-prevention drug Aggrenox off the market slammed discovery requests regarding several other drugs with which it "evidently" competes, calling the requests "enormously burdensome."
August 17, 2015
Aggrenox Plaintiffs Say Boehringer's Lidoderm Take Is Wrong

Drugstore chains accusing Boehringer Ingelheim Pharmaceuticals Inc. of scheming to keep generic versions of the stroke drug Aggrenox off the market shot back at the defendants' arguments that a recent ruling fails to bolster their case, telling a Connecticut federal court Monday that order supports their injunction bid.
August 10, 2015
Humana, Worker Funds Fight To Preserve Pay-For-Delay MDL

Humana Inc. and a group of employee health funds separately asked a Connecticut federal judge Friday to deny dismissal bids by Teva Pharmaceuticals USA Inc. and Boehringer Ingelheim Pharmaceuticals Inc. in multidistrict litigation accusing them of a pay-for-delay scheme over a generic version of stroke drug Aggrenox.
July 22, 2015
Teva, Boehringer Get Quick Appeal In Pay-For-Delay MDL

A Connecticut federal judge overseeing multidistrict litigation alleging Teva Pharmaceuticals USA Inc. and Boehringer Ingelheim Pharmaceuticals Inc. engaged in a pay-for-delay scheme over a generic version of stroke drug Aggrenox cleared the drugmakers to immediately appeal an order that kept intact most federal claims against them.
June 03, 2015
Teva, Others Seek To Nix Retailers' Pay-For-Delay Suits

Teva Pharmaceuticals USA Inc., Boehringer Ingelheim Pharmaceuticals Inc. and other pharmaceutical companies accused in multidistrict litigation of engaging in a pay-for-delay scheme over the stroke drug Aggrenox told a Connecticut federal court to toss complaints by six retailers because they didn't show they directly bought the drug.
April 27, 2015
Humana Urges Court Not To Allow Drug Cos.' Aggrenox Appeal

A Connecticut federal court should not send its recent order largely refusing to dismiss a pay-for-delay suit over stroke drug Aggrenox to the Second Circuit for interlocutory review, Humana Inc. argued Monday.
April 06, 2015
Drug Cos. Want 2nd Circ. To Hear Bid To Nix Aggrenox Claims

Teva Pharmaceuticals USA Inc. and Boehringer Ingelheim Pharmaceuticals Inc. have asked a Connecticut court to send its recent order largely refusing to dismiss a pay-for-delay suit over stroke drug Aggrenox to the Second Circuit for review.